As an effective inhibitor of p53 activation, targeting the MDM2-p53 interaction by small molecules to reactivate p53 has emerged as an attractive therapeutic strategy for cancer therapy, especially for tumor cells with wild-type or functional p53 (Shangary and Wang, 2008). This evidence concerns the gene TP53 and neoplasm.